Global Transarterial Chemoembolization (TACE) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Get Exclusive Sample PDF of this Report Here

Transarterial Chemoembolization (TACE) Market Size

• The global Transarterial Chemoembolization (TACE) market size was valued at USD 2.47 billion in 2024 and is expected to reach USD 4.67 billion by 2032, at a CAGR of 8.25% during the forecast period
• The market growth is largely fueled by the increasing incidence of liver cancer and the rising preference for minimally invasive cancer therapies, positioning TACE as a standard treatment for intermediate-stage hepatocellular carcinoma
• Furthermore, technological advancements in drug delivery systems, growing awareness of interventional oncology, and expanding healthcare infrastructure in emerging markets are enhancing the accessibility and effectiveness of TACE procedures. These converging factors are accelerating the adoption of TACE, thereby significantly boosting the industry's growth

Transarterial Chemoembolization (TACE) Market Analysis

• Transarterial Chemoembolization (TACE), a targeted therapy combining chemotherapy and embolization, is becoming a cornerstone treatment for intermediate-stage hepatocellular carcinoma (HCC), owing to its minimally invasive nature and ability to deliver localized treatment with limited systemic toxicity
• The escalating demand for TACE is primarily fueled by the rising global incidence of liver cancer, advancements in image-guided interventions, and increasing physician preference for non-surgical cancer management techniques
• North America dominated the Transarterial Chemoembolization (TACE) market with the largest revenue share of 39.2% in 2024, characterized by high awareness of interventional oncology treatments, advanced healthcare infrastructure, and significant R&D investments. The U.S. continues to witness growth in TACE procedures, supported by expanding access to specialized cancer centers and the integration of precision medicine in liver cancer care
• Asia-Pacific is expected to be the fastest growing region in the Transarterial Chemoembolization (TACE) market during the forecast period due to a high burden of liver cancer, increasing healthcare investments, and rising adoption of minimally invasive therapies
• Conventional TACE (cTACE) segment dominated the Transarterial Chemoembolization (TACE) market with a market share of 58% in 2024, driven by its widespread clinical use, established efficacy, and lower cost compared to drug-eluting bead TACE (DEB-TACE)

Report Scope and Transarterial Chemoembolization (TACE) Market Segmentation   

Get Exclusive Sample PDF of this Report Here

Transarterial Chemoembolization (TACE) Market Trends

“Advancement of Image-Guided and Drug-Eluting Technologies”

• A significant and accelerating trend in the global Transarterial Chemoembolization (TACE) market is the growing adoption of advanced imaging techniques and the development of drug-eluting bead (DEB) technologies, which enhance the precision, safety, and efficacy of localized chemotherapy for liver cancer patients
  • For instance, Siemens Healthineers and Philips have introduced AI-enhanced interventional radiology platforms that allow real-time tumor targeting and optimized embolization outcomes. Similarly, Biocompatibles UK Ltd. (a BTG International group company) has seen increased use of its LC Bead® in DEB-TACE procedures, which offers sustained drug release and reduced systemic toxicity
• Innovations in drug-eluting bead formulations, such as CalliSpheres® and DC Bead LUMI™, enable improved visualization and targeted delivery, resulting in better tumor response and reduced side effects. In addition, AI-assisted imaging systems are improving pre-procedural planning, enabling oncologists to tailor embolization based on individual patient anatomy and tumor vascularity
• The integration of these technologies facilitates more effective and personalized treatment, driving clinician confidence and expanding the use of TACE beyond hepatocellular carcinoma to secondary liver tumors
• This trend toward precision oncology and minimally invasive intervention is redefining interventional cancer treatment protocols. As a result, leading players such as Guerbet and Terumo Corporation are investing in image-guided drug delivery innovations and expanding their embolization product portfolios to capture emerging demand in both developed and developing markets
• The demand for technologically advanced and targeted TACE procedures is rising sharply across oncology centers worldwide, as healthcare providers increasingly aim for improved patient outcomes, shorter recovery times, and reduced hospital stays

Transarterial Chemoembolization (TACE) Market Dynamics

Driver

“Rising Liver Cancer Incidence and Demand for Minimally Invasive Oncology Procedures”

• The increasing global incidence of liver cancer, especially hepatocellular carcinoma (HCC), is a major driver fueling demand for TACE as a preferred first-line therapy for intermediate-stage tumors in patients who are not surgical candidates
  • For instance, in January 2024, Boston Scientific expanded access to its interventional oncology product line with its Embosphere® Microspheres, designed to enhance embolic delivery during TACE procedures. Such innovations by major companies are expected to support TACE market expansion throughout the forecast period
• As the burden of liver cancer grows in Asia, Europe, and North America, healthcare providers are turning to TACE for its ability to localize treatment, reduce systemic toxicity, and extend patient survival without extensive surgical intervention
• The aging population, rising alcohol consumption, and growing prevalence of hepatitis B and C infections are contributing to the increasing number of liver cancer cases, especially in emerging markets
• Furthermore, TACE offers a shorter hospital stay, fewer complications, and faster recovery times compared to traditional surgical approaches, making it a viable option for elderly patients and those with comorbidities. The expanding availability of interventional radiology services and increasing physician familiarity with the procedure further boost its adoption in tertiary care hospitals and cancer centers

Restraint/Challenge

“Procedure-Related Complications and Limited Access in Low-Resource Settings”

• Despite its benefits, TACE procedures carry potential risks such as post-embolization syndrome (PES), hepatic dysfunction, and vascular complications, which can limit its application in patients with poor liver reserve or advanced cirrhosis
  • For instance, studies in 2023 reported that up to 60% of patients may experience PES after TACE, including symptoms such as abdominal pain, fever, and nausea. This necessitates careful patient selection and post-procedural care, which may not be feasible in all healthcare environments
• In addition, limited access to specialized interventional oncology equipment, trained radiologists, and high procedural costs restrict the adoption of TACE in many low- and middle-income countries
• Regulatory barriers, reimbursement uncertainties, and the lack of standardized treatment protocols across regions further challenge the widespread uptake of TACE therapy
• Overcoming these hurdles will require collaborative efforts in physician training, public-private partnerships to expand oncology infrastructure, and the development of cost-effective TACE kits suitable for broader clinical environments. Continued investment in safety-enhancing technologies and awareness campaigns will also be critical to mitigating risks and accelerating market growth globally

Transarterial Chemoembolization (TACE) Market Scope

The market is segmented on the basis of procedure type, product type, indication, and end-user.

• By Procedure Type

On the basis of procedure type, the Transarterial Chemoembolization (TACE) market is segmented into Conventional TACE (cTACE) and Drug-Eluting Bead TACE (DEB-TACE). The conventional TACE segment dominated the market with the largest market revenue share of 58% in 2024, driven by its clinical effectiveness, cost-efficiency, and widespread availability in hospitals across various regions. Conventional TACE remains the preferred option due to its flexibility in chemotherapeutic agent selection and physician familiarity with the technique, making it a standard treatment for intermediate-stage hepatocellular carcinoma.

The DEB-TACE segment is anticipated to witness the fastest growth rate of 9.6% from 2025 to 2032, fueled by rising adoption of advanced embolization techniques and the demand for improved safety and efficacy. Drug-eluting beads provide targeted drug delivery with fewer systemic side effects, making them increasingly popular in both primary and metastatic liver cancer treatment. The expanding portfolio of DEB products and favorable clinical outcomes are accelerating growth in this segment.

• By Product Type

On the basis of product type, the Transarterial Chemoembolization (TACE) market is segmented into Chemotherapeutic Agents, Radiotherapeutic Agents, and Drug-Eluting Particles. The drug-eluting particles segment held the largest market revenue share in 2024, driven by the growing preference for DEB-TACE procedures. These particles allow for sustained and localized chemotherapy delivery, reducing off-target toxicity and enhancing treatment efficacy. Products such as DC Bead® and CalliSpheres® are widely adopted due to their proven clinical benefits and procedural consistency.

The radiotherapeutic agents segment is expected to witness the fastest CAGR from 2025 to 2032, supported by increasing research into radioembolization as a complementary or alternative approach to traditional chemoembolization. Radiotherapeutic microspheres are gaining traction in precision oncology, especially in cases where patients are ineligible for surgery or chemotherapy. Their growing role in targeted liver tumor therapy is expected to drive segment growth significantly.

• By Indication

On the basis of indication, the Transarterial Chemoembolization (TACE) market is segmented into Unresectable Hepatocellular Carcinoma (HCC) and Early-Stage Hepatocellular Carcinoma (HCC). The unresectable HCC segment dominated the market with the largest market revenue share in 2024, as TACE is the standard of care for patients with intermediate-stage liver cancer who are not candidates for surgical resection or transplantation. High liver cancer incidence globally and limited access to surgical treatment further drive demand in this segment.

The early-stage HCC segment is anticipated to witness the fastest growth rate from 2025 to 2032, driven by the increasing use of TACE as a bridging or downstaging therapy prior to surgery or transplant. Early detection through improved screening protocols and the rising interest in multimodal therapy strategies are expanding the application of TACE in early-stage liver cancer management.

• By End User

On the basis of end-user, the Transarterial Chemoembolization (TACE) market is segmented into hospitals and clinics and cancer research centers. The hospitals and clinics segment held the largest market revenue share in 2024, owing to the high procedural volume, access to advanced imaging and interventional radiology infrastructure, and presence of multidisciplinary oncology teams. TACE is widely performed in hospital settings due to its complex procedural requirements and need for post-procedure monitoring.

The cancer research centers segment is expected to witness the fastest CAGR from 2025 to 2032, driven by the increasing number of clinical trials exploring combination therapies and novel embolization techniques. These institutions play a critical role in advancing interventional oncology and serve as early adopters of cutting-edge TACE technologies, thereby contributing to innovation and market expansion.

Transarterial Chemoembolization (TACE) Market Regional Analysis

• North America dominated the Transarterial Chemoembolization (TACE) market with the largest revenue share of 39.2% in 2024, characterized by high awareness of interventional oncology treatments, advanced healthcare infrastructure, and significant R&D investments. The U.S. continues to witness growth in TACE procedures, supported by expanding access to specialized cancer centers and the integration of precision medicine in liver cancer care
• Patients and providers in the region place high value on targeted treatment options that reduce systemic side effects and improve recovery times, making TACE an attractive option for managing intermediate-stage hepatocellular carcinoma
• This widespread adoption is further supported by advanced healthcare systems, ongoing technological innovation in embolization techniques, and strong reimbursement frameworks, establishing TACE as a leading interventional oncology procedure across major U.S. and Canadian cancer care centers

U.S. Transarterial Chemoembolization (TACE) Market Insight

The U.S. Transarterial Chemoembolization (TACE) market captured the largest revenue share of 83% in 2024 within North America, fueled by a high incidence of liver cancer and the presence of cutting-edge interventional radiology infrastructure. Growing preference for minimally invasive, localized treatments among oncologists and patients supports the increasing adoption of TACE procedures. The country’s strong reimbursement ecosystem, continuous clinical research, and integration of AI in imaging and embolization workflows further drive the TACE market forward. Moreover, the expanding application of TACE as a bridge therapy for transplantation enhances its clinical value in advanced oncology care.

Europe Transarterial Chemoembolization (TACE) Market Insight

The Europe Transarterial Chemoembolization (TACE) market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by rising liver cancer cases and the adoption of image-guided therapeutic interventions. The growing focus on non-surgical treatment options in oncology, alongside government-funded cancer programs, is facilitating the adoption of TACE across healthcare systems. In addition, increasing collaborations between hospitals and medtech companies to standardize interventional oncology protocols are fostering innovation and market growth across both public and private healthcare institutions.

U.K. Transarterial Chemoembolization (TACE) Market Insight

The U.K. Transarterial Chemoembolization (TACE) market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by early diagnosis programs and the country’s shift towards less invasive cancer treatment options. The National Health Service’s emphasis on precision medicine and the integration of TACE into liver cancer care pathways are enhancing accessibility. Furthermore, the presence of specialized cancer centers and robust clinical trial activity support the wider adoption of advanced TACE techniques and embolic agents.

Germany Transarterial Chemoembolization (TACE) Market Insight

The Germany Transarterial Chemoembolization (TACE) market is expected to expand at a considerable CAGR during the forecast period, fueled by a highly developed healthcare system and strong demand for technologically advanced cancer therapies. With rising awareness of interventional oncology and increasing patient preference for localized therapies, hospitals in Germany are investing in next-generation TACE technologies. Emphasis on quality standards, data-driven treatment protocols, and sustainable medical solutions further contributes to the country’s leadership in Europe’s TACE market.

Asia-Pacific Transarterial Chemoembolization (TACE) Market Insight

The Asia-Pacific Transarterial Chemoembolization (TACE) market is poised to grow at the fastest CAGR of 10.4% during the forecast period of 2025 to 2032, driven by a high burden of hepatocellular carcinoma, increasing healthcare investments, and expanding interventional oncology capabilities in countries such as China, Japan, and India. The region benefits from improved access to diagnostic imaging, rising awareness of liver cancer treatments, and support from public health initiatives. As APAC strengthens its healthcare infrastructure and medical device manufacturing, TACE becomes more accessible across both urban and emerging markets.

Japan Transarterial Chemoembolization (TACE) Market Insight

The Japan Transarterial Chemoembolization (TACE) market is gaining momentum due to the country’s advanced medical technologies, aging population, and increasing liver disease burden. High adoption of precision interventional therapies and strong clinical trial participation support the integration of TACE in cancer treatment protocols. Japan’s focus on reducing hospital stays and enhancing quality of life for cancer patients aligns with the minimally invasive nature of TACE, further driving demand in both public and private medical institutions.

India Transarterial Chemoembolization (TACE) Market Insight

The India Transarterial Chemoembolization (TACE) market accounted for the largest market revenue share in Asia-Pacific in 2024, attributed to rising liver cancer prevalence, expanding cancer care infrastructure, and growing awareness of interventional treatments. TACE is being increasingly adopted in both tier-1 hospitals and regional oncology centers due to its affordability and effectiveness. Government health initiatives promoting early cancer diagnosis and partnerships with global medtech companies to improve access to embolization technologies are key factors propelling market growth in India.

Transarterial Chemoembolization (TACE) Market Share

The Transarterial Chemoembolization (TACE) industry is primarily led by well-established companies, including:

• Questex (U.S.)
• Siemens Healthineers AG (Germany)
• Intermountain Healthcare (U.S.)
• Provincial Health Services Authority (Canada)
• Cancer Research Institute (U.S.)
• Bellicum Pharmaceuticals Inc. (U.S.)
• Boston Scientific Corporation (U.S.)
• Hikma Pharmaceuticals PLC (Jordan)
• Isofol Medical AB (publ) (Sweden)
• Nippon Kayaku Co. Ltd. (Japan)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Sirtex SIR-Spheres Pty Ltd. (Australia)
• Spectrum Pharmaceuticals, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Bayer AG (Germany)
• Hepion Pharmaceuticals (U.S.)
• Polaris Pharmaceuticals (U.S.)
• Chugai Pharmaceutical Co., Ltd. (Japan)
• Merck & Co., Inc. (U.S.)

What are the Recent Developments in Global Transarterial Chemoembolization (TACE) Market?

• In May 2023, Terumo Corporation announced the global expansion of its LifePearl microspheres, an advanced drug-eluting embolic platform used in TACE procedures for the treatment of hepatocellular carcinoma. The move aims to increase access to precision embolization therapy in new markets, particularly in Asia and Latin America. Terumo’s expansion underscores its commitment to enhancing interventional oncology care by offering innovative, clinically validated solutions that improve patient outcomes in liver cancer management
• In April 2023, Guerbet, a global specialist in diagnostic and interventional imaging, launched its Embozene TANDEM microspheres in Europe, designed for targeted chemoembolization. The product integrates color-coded, drug-loadable microspheres for improved visibility and consistency during TACE procedures. This development aligns with Guerbet’s strategic focus on expanding its interventional oncology portfolio and reinforces its role in advancing minimally invasive cancer therapies
• In March 2023, Boston Scientific Corporation announced the results of a multi-center clinical study evaluating the effectiveness of its Embosphere Microspheres in combination with systemic therapies for intermediate-stage HCC. The study demonstrated improved patient response rates and longer progression-free survival, supporting broader adoption of TACE as part of multimodal treatment strategies. This highlights Boston Scientific's ongoing investment in evidence-based oncology solutions and combination therapy research
• In February 2023, Medtronic partnered with leading cancer institutes in India to introduce training programs focused on interventional oncology techniques, including TACE. This initiative aims to strengthen the skillset of interventional radiologists and expand access to TACE in developing regions. By investing in education and clinical capacity-building, Medtronic is contributing to the wider adoption of minimally invasive treatments and improved liver cancer outcomes across emerging markets
• In January 2023, BTG International (a part of Boston Scientific) received expanded regulatory approval in select European countries for its LC Bead LUMI radiopaque drug-eluting beads, allowing for enhanced visualization during TACE procedures. This innovation facilitates real-time monitoring of embolization, optimizing treatment precision and post-procedure assessment. The development marks a significant advancement in TACE delivery, reinforcing BTG’s commitment to precision medicine in interventional oncology

SKU-58999